DÄ internationalArchiveReferences
References

Review article

Autoantibody-Mediated Encephalitis

Dtsch Arztebl Int 2018; 115: 666-73. DOI: 10.3238/arztebl.2018.0666

Wandinger, K; Leypoldt, F; Junker, R

1.Royl G, Ploner CJ, Möckel M, Leithner C: [Neurological chief complaints in an emergency room]. Nervenarzt 2010; 81: 1226–30 CrossRef MEDLINE
2.Ryan DJ, O‘Regan NA, Caoimh RÓ, et al.: Delirium in an adult acute hospital population: predictors, prevalence and detection. BMJ Open 2013 ; 3: e001772 CrossRef MEDLINE PubMed Central
3.Inouye SK, Westendorp RGJ, Saczynski JS: Delirium in elderly people. Lancet 2014; 383: 911–22 CrossRef
4.Leypoldt F, Armangue T, Dalmau J: Autoimmune encephalopathies. Ann N Y Acad Sci 2015; 1338: 94–114 CrossRef MEDLINE PubMed Central
5.Escudero D, Guasp M, Ariño H, et al.: Antibody-associated CNS syndromes without signs of inflammation in the elderly. Neurology 2017; 89: 1471–5 CrossRef MEDLINE
6.Thompson J, Bi M, Murchison AG, et al.: The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018; 141: 348–56 CrossRef MEDLINE PubMed Central
7.Irani SR, Michell AW, Lang B, et al.: Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892–900 CrossRef MEDLINE
8.Graus F, Titulaer MJ, Balu R, et al.: A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391–404 CrossRef
9.Gaspard N, Foreman BP, Alvarez V, et al.: New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015; 85: 1604–13 CrossRef MEDLINE PubMed Central
10.van Sonderen A, Ariño H, Petit-Pedrol M, et al.: The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016; 87: 521–8 CrossRef MEDLINE PubMed Central
11.Ariño H, Armangue T, Petit-Pedrol M, et al.: Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016; 87: 759–65 CrossRef MEDLINE PubMed Central
12.Dalmau J, Tüzün E, Wu HY, et al.: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25–36 CrossRef MEDLINE PubMed Central
13.Dalmau J: NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias Lecture. Neurology 2016; 87: 2471–82 CrossRef MEDLINE PubMed Central
14.Granerod J, Ambrose HE, Davies NW, et al.: Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10: 835–44 CrossRef
15.Shin JW, Koo YS, Kim YS, et al.: Clinical characterization of unknown/cryptogenic status epilepticus suspected as encephalitis: a multicenter cohort study. J Neuroimmunol 2018; 315: 1–8 CrossRef MEDLINE
16.Atmaca MM, Tüzün E, Erdağ E, Bebek N, Baykan B, Gurses C: Investigation of anti-neuronal antibodies in status epilepticus of unknown etiology: a prospective study. Acta Neurol Belg 2017; 117: 841–84 CrossRef MEDLINE
17.Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63–74 CrossRef
18.Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J: Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 2011; 77: 589–93 CrossRef MEDLINE PubMed Central
19.van Sonderen A, Roelen DL, Stoop JA, et al.: Anti-LGI1 encephalitis is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol 2017; 81: 193–8 CrossRef MEDLINE
20.Armangue T, Leypoldt F, Málaga I, et al.: Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol 2014; 75: 317–23 CrossRef MEDLINE PubMed Central
21.Mueller SH, Färber A, Prüss H, et al.: Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis. Ann Neurol 2018; 83: 863–9 CrossRef MEDLINE
22.Leypoldt F, Höftberger R, Titulaer MJ, et al.: Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response. JAMA Neurol 2015; 72: 180–6 CrossRef MEDLINE PubMed Central
23.Gresa-Arribas N, Titulaer MJ, Torrents A, et al.: Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13: 167–77 CrossRef
24.Hughes EG, Peng X, Gleichman AJ, et al.: Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010; 30: 5866–75 CrossRef MEDLINE PubMed Central
25.Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ: Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 76: 108–19 CrossRef MEDLINE PubMed Central
26.Planaguma J, Leypoldt F, Mannara F, et al.: Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 2015; 138: 94–109 CrossRef MEDLINE PubMed Central
27.Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C: Imaging of autoimmune encephalitis—relevance for clinical practice and hippocampal function. Neuroscience 2015; 309: 68–83 CrossRef MEDLINE
28.Titulaer MJ, McCracken L, Gabilondo I, et al.: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157–65 CrossRef
29.Wandinger KP, Klingbeil C, Gneiss C, et al.: New serological markers for the differential diagnosis of autoimmune limbic encephalitis. Journal of Laboratory Medicine 2011; 35: 329–42.
30. Dahm L, Ott C, Steiner J, et al.: Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 2014; 76: 82–94 CrossRef MEDLINE
31.Hansen HC, Klingbeil C, Dalmau J, Li W, Weißbrich B, Wandinger KP: Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol 2013; 70: 117–9 CrossRef MEDLINE PubMed Central
32.Gresa-Arribas N, Planaguma J, Petit-Pedrol M, et al.: Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology 2016; 86: 2235–42 CrossRef MEDLINE PubMed Central
33.Sabater L, Gaig C, Gelpi E, et al.: A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014; 13: 575–86 CrossRef
34.Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al.: Antibodies to metabotropic glutamate receptor 5 in the ophelia syndrome. Neurology 2011; 77: 1698–701 CrossRef MEDLINE PubMed Central
35.Finke C, Kopp UA, Scheel M, et al.: Functional and structural brain changes in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2013; 74: 284–96 MEDLINE
36.Finke C, Kopp UA, Pajkert A, et al.: Structural hippocampal damage following anti-N-methyl-D-aspartate receptor encephalitis. Biol Psychiatry 2016; 79: 727–34 CrossRef MEDLINE
37.Finke C, Prüss H, Heine J, et al.: Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017; 74: 50–9 MEDLINE
38.Lee WJ, Lee ST, Moon J, et al.: Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics 2016; 13: 824–32 CrossRef MEDLINE PubMed Central
39.Scheibe F, Prüss H, Mengel AM, et al.: Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88: 366–70 CrossRef MEDLINE
40.Dalmau J, Graus F: Antibody-mediated encephalitis. N Engl J Med 2018; 378: 840–51. CrossRef MEDLINE
e1. McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK: Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc 2003; 51: 591–8 CrossRef
e2. Inouye SK, Rushing JT, Foreman MD, Palmer RM, Pompei P: Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med 1998; 13: 234–42 CrossRef PubMed Central
e3.Francis J: Delirium in older patients. J Am Geriatr Soc 1992; 40: 829–38 CrossRef
e4.Bien CG, Mirzadjanova Z, Baumgartner C, et al.: Anti-contactin-associated protein-2 encephalitis: relevance of antibody titres, presentation and outcome. Eur J Neurol 2017; 24: 175–86 CrossRef MEDLINE
e5. Joubert B, Saint-Martin M, Noraz N, et al.: Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 2016; 73: 1115–24 CrossRef MEDLINE
e6.Corsellis JA, Goldberg GJ, Norton AR: “Limbic encephalitis” and its association with carcinoma. Brain 1968; 91: 481–96 CrossRef
e7.Darnell RB, Posner JB: Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006; 33: 270–98 CrossRef MEDLINE
e8.Ances BM, Vitaliani R, Taylor RA, et al.: Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005; 128: 1764–77 CrossRef MEDLINE PubMed Central
e9.Jarius S, Wandinger KP, Horn S, Heuer H, Wildemann B: A new purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation 2010; 7: 21 CrossRef MEDLINE PubMed Central
e10. Ogawa R, Nakashima I, Takahashi T, et al.: MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017; 4: e322.
e11.Hamid SHM, Whittam D, Saviour M, et al.: Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease. JAMA Neurol 2018; 75: 65–71 CrossRef MEDLINE